Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Shareholders to Recover $55 Million in Rare Jury Verdict
Securities Group Of The Year: Robbins Geller
Biotech Entrepreneur's Fortune Nearly Doubles After Strong Clinical Trials For Cancer Treatment